Henry Schein (NASDAQ:HSIC – Free Report) had its price target lowered by Robert W. Baird from $92.00 to $82.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an outperform rating on the stock.
A number of other research analysts also recently commented on the stock. Barrington Research lowered their price target on shares of Henry Schein from $92.00 to $82.00 and set an outperform rating for the company in a report on Wednesday. Piper Sandler reiterated an overweight rating and issued a $86.00 target price on shares of Henry Schein in a report on Friday, June 21st. Baird R W upgraded Henry Schein from a hold rating to a strong-buy rating in a research report on Monday, July 22nd. Evercore ISI dropped their price objective on shares of Henry Schein from $72.00 to $70.00 and set an in-line rating for the company in a research note on Wednesday. Finally, UBS Group lowered their target price on shares of Henry Schein from $82.00 to $80.00 and set a neutral rating for the company in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Hold and an average target price of $77.90.
Get Our Latest Stock Analysis on HSIC
Henry Schein Price Performance
Henry Schein (NASDAQ:HSIC – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.01. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The company had revenue of $3.10 billion for the quarter, compared to analysts’ expectations of $3.27 billion. During the same quarter in the previous year, the business posted $1.31 earnings per share. Henry Schein’s quarterly revenue was up .0% on a year-over-year basis. On average, equities analysts predict that Henry Schein will post 5.16 earnings per share for the current year.
Institutional Investors Weigh In On Henry Schein
Several large investors have recently added to or reduced their stakes in HSIC. Edgestream Partners L.P. purchased a new position in shares of Henry Schein during the second quarter worth approximately $1,418,000. Dimensional Fund Advisors LP raised its position in Henry Schein by 10.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,634,384 shares of the company’s stock valued at $104,764,000 after purchasing an additional 149,517 shares in the last quarter. Keene & Associates Inc. lifted its holdings in shares of Henry Schein by 14.3% in the 2nd quarter. Keene & Associates Inc. now owns 5,150 shares of the company’s stock worth $330,000 after buying an additional 645 shares during the period. Thompson Siegel & Walmsley LLC bought a new position in shares of Henry Schein during the 2nd quarter worth $46,683,000. Finally, Oppenheimer Asset Management Inc. increased its stake in shares of Henry Schein by 12.5% during the second quarter. Oppenheimer Asset Management Inc. now owns 5,459 shares of the company’s stock valued at $350,000 after buying an additional 606 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also
- Five stocks we like better than Henry Schein
- How to buy stock: A step-by-step guide for beginnersÂ
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- How to Use the MarketBeat Excel Dividend Calculator
- MarketBeat Week in Review – 8/5 – 8/9
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.